IMMUCELL CORP /DE/ financial metrics

Period Q3 2026 · Filed 12 Nov 2026

Key metrics snapshot

Return On Invested Capital

13%

Trailing 12 months · Through 30 Sep 2026

YoY relative change: +108%

SEC metric history

Return On Equity

6%

Trailing 12 months · Through 30 Sep 2026

YoY relative change: -27%

SEC metric history

Return On Assets

4.2%

Trailing 12 months · Through 30 Sep 2026

YoY relative change: -22%

SEC metric history

Operating Margin

14%

Trailing 12 months · Through 30 Sep 2026

YoY relative change: +73%

SEC metric history

Current Ratio

4.61x

Period-end balance · Through 30 Sep 2026

YoY relative change: +9.5%

SEC metric history

Quick Ratio

2.41x

Period-end balance · Through 30 Sep 2026

YoY relative change: +50%

SEC metric history

Debt-to-equity

0.28x

Period-end balance · Through 30 Sep 2026

YoY relative change: -24%

SEC metric history

Profitability

Metric Latest value YoY relative change
Return On Invested Capital 13%
Trailing 12 months · 30 Sep 2026
+108%
Return On Equity 6%
Trailing 12 months · 30 Sep 2026
-27%
Return On Assets 4.2%
Trailing 12 months · 30 Sep 2026
-22%
Operating Margin 14%
Trailing 12 months · 30 Sep 2026
+73%

Financial Health

Metric Latest value YoY relative change
Current Ratio 4.61x
Period-end balance · 30 Sep 2026
+9.5%
Quick Ratio 2.41x
Period-end balance · 30 Sep 2026
+50%
Debt-to-equity 0.28x
Period-end balance · 30 Sep 2026
-24%

Growth

Metric Latest value YoY relative change
Revenues YoY 46%
Quarter · 30 Sep 2026
NetIncomeLoss YoY -19%
Trailing 12 months · 30 Sep 2026

Share Metrics

Metric Latest value YoY relative change
Entity Common Stock, Shares Outstanding 9,091,361
Period-end balance · 30 Oct 2026
+0.5%
Common Stock, Shares, Outstanding 9,090,361
Period-end balance · 30 Sep 2026
+0.49%
Common Stock, Value, Issued $910,563
Period-end balance · 30 Sep 2026
0%
Weighted Average Number of Shares Outstanding, Basic 9,084,358
Reported period · 30 Sep 2026
+0.43%
Weighted Average Number of Shares Outstanding, Diluted 9,297,507
Reported period · 30 Sep 2026
+2.8%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY relative change
Accounts Receivable, after Allowance for Credit Loss, Current $3,373,759
Period-end balance · 30 Sep 2026
+32%
Assets $47,958,262
Period-end balance · 30 Sep 2026
+13%
Assets, Current $21,577,479
Period-end balance · 30 Sep 2026
+28%
Cash and Cash Equivalents, at Carrying Value $7,914,406
Period-end balance · 30 Sep 2026
+104%
Common Stock, Par or Stated Value Per Share 0.1
Period-end balance · 30 Sep 2026
0%
Common Stock, Shares Authorized 15,000,000
Period-end balance · 30 Sep 2026
0%
Common Stock, Shares, Issued 9,105,622
Period-end balance · 30 Sep 2026
0%
Cost of Revenue $19,649,422
Trailing 12 months · 30 Sep 2026
+43%
Depreciation $2,159,809
Trailing 12 months · 30 Sep 2026
-19%
Depreciation, Depletion and Amortization $2,170,902
Trailing 12 months · 30 Sep 2026
-35%
Earnings Per Share, Basic 0.19
Trailing 12 months · 30 Sep 2026
-34%
Earnings Per Share, Diluted 0.19
Trailing 12 months · 30 Sep 2026
-34%
General and Administrative Expense $4,826,838
Trailing 12 months · 30 Sep 2026
+84%
Goodwill $95,557
Period-end balance · 30 Sep 2026
0%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,924,174
Trailing 12 months · 30 Sep 2026
-18%
Income Tax Expense (Benefit) $44,543
Trailing 12 months · 30 Sep 2026
+211%
Inventory, Net $9,857,047
Period-end balance · 30 Sep 2026
+0.56%
Liabilities $15,184,077
Period-end balance · 30 Sep 2026
-4.7%
Liabilities and Equity $47,958,262
Period-end balance · 30 Sep 2026
+4.9%
Liabilities, Current $4,680,612
Period-end balance · 30 Sep 2026
+17%
Nonoperating Income (Expense) -$2,879,890
Trailing 12 months · 30 Sep 2026
-31017%
Operating Income (Loss) $4,804,064
Trailing 12 months · 30 Sep 2026
+106%
Operating Lease, Liability, Current $124,235
Period-end balance · 30 Sep 2026
+51%
Operating Lease, Liability, Noncurrent $3,987,398
Period-end balance · 30 Sep 2026
-1.1%
Operating Lease, Right-of-Use Asset $4,337,977
Period-end balance · 30 Sep 2026
-1.8%
Other Assets, Noncurrent $29,817
Period-end balance · 30 Sep 2026
-33%
Property, Plant and Equipment, Net $21,917,432
Period-end balance · 30 Sep 2026
-10%
Research and Development Expense $1,372,975
Trailing 12 months · 30 Sep 2026
-56%
Retained Earnings (Accumulated Deficit) -$10,474,980
Period-end balance · 30 Sep 2026
+15%
Revenue from Contract with Customer, Excluding Assessed Tax $33,209,357
Trailing 12 months · 30 Sep 2026
+46%
Selling and Marketing Expense $4,556,058
Trailing 12 months · 30 Sep 2026
+38%
Share-based Payment Arrangement, Expense $878,054
Trailing 12 months · 30 Sep 2026
+236%
Stockholders' Equity Attributable to Parent $32,774,185
Period-end balance · 30 Sep 2026
+10%
Comparisons, sources and research notes
Sources and sharing

ICCC - IMMUCELL CORP /DE/ Financial Facts

Context
Latest metrics period: Q3 2026
Latest reported value
Return On Invested Capital 13%

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Tracking and update notes

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q3 2026
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q3 2026.
  • Most recent SEC facts end date on this page: 30 Oct 2026.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Latest update

Latest update for ICCC - IMMUCELL CORP /DE/

New fact period available

Latest financial period: Q3 2026. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

12 Nov 2026

Page type

Company facts

Latest period

Q3 2026

SEC-backed company facts were refreshed from filings filed on 12 Nov 2026.

Benchmark Context

How Return On Invested Capital compares

Return On Invested Capital is up about 108% versus the comparable prior period.

Compared with

Compared with IMMUCELL CORP /DE/'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Return On Invested Capital already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q3 2026.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

How to read key metrics on this page

These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.

Plain-English Guide

How to read Revenue on this page

Revenue is the sales a company reports from customers before most expenses are subtracted.

Why people care

People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.

How to read it

Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.

Compare next

Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.

Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.

Plain-English Guide

How to read Net Income on this page

Net income is profit after operating costs, interest, taxes, and other non-operating items.

Why people care

It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.

How to read it

Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.

Compare next

Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.

Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.

Filing notes and source

Key facts

  • ICCC - IMMUCELL CORP /DE/ financial facts use SEC filings; any third-party reference is labeled separately.
  • Latest metrics period on this page: Q3 2026.
  • Headline metric: Return On Invested Capital 13%.

Change

  • Return On Invested Capital YoY relative change: +108%.
  • Most recent SEC facts end date: 30 Oct 2026.

Research use

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.

Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

View source filing

Latest financial snapshot (2026-10-30) highlights Return On Invested Capital 13.2%, Return On Equity 6.0%, and Return On Assets 4.2%.

Valuation Snapshot

SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.

No market comparison No market comparison Medium confidence

USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.

Fair value per share

n/a

Market price

$10.52

ICCC - Local security

PEG ratio

13.0x

P/E 52.0x / growth 4%

DCF Growth Assumption

Enterprise value

$78.67M

Equity value

n/a

DCF fair value scenarios

Bear

n/a

No market comparison
Growth
1%
Discount
11%
Terminal
2%

Base

n/a

No market comparison
Growth
4%
Discount
10%
Terminal
2.5%

Bull

n/a

No market comparison
Growth
7%
Discount
9%
Terminal
3%

Base growth: DCF Growth Assumption.

Key valuation metrics

EV/Revenue

n/a

Local security market EV / SEC revenue

Market enterprise value is unavailable

EV/EBITDA

n/a

Local security market EV / SEC EBITDA

Market enterprise value is unavailable

P/E

52.0x

Local security market price / SEC EPS

P/S

2.9x

Local security market cap / SEC revenue

P/B

3.0x

Local security market cap / SEC equity

PEG

13.0x

P/E / DCF Growth Assumption

Core assumptions

Projection
5 years
FCF growth
4%
Discount rate
10%
Terminal growth
2.5%

SEC fact inputs

DCF base FCF
$5.4M
Trailing SEC FCF
Reported FCF
$5.4M
Net income
$1.88M
EBITDA
$6.97M
Cash
$7.91M
Debt
n/a
Equity
$32.77M
Shares
9,297,507
Input periods, units and SEC sources

Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.

  • Operating cash flow: 7,830,549.0 USD · through 2026-09-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
  • Capital expenditures: 2,428,736.0 USD · through 2026-09-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
  • Cash and equivalents: 7,914,406.0 USD · through 2026-09-30 SEC source
  • Debt: unavailable on a verified comparable basis

Data confidence notes

  • Debt unavailable: no complete usd debt balance at the latest balance date
  • Dcf base free cash flow: dcf base starts from trailing sec free cash flow
  • Debt missing: equity value and market ev unavailable

Compare This Company Through SEC-backed Metrics

Use these links to compare ICCC - IMMUCELL CORP /DE/ against other SEC filers on the same metric, then verify the company history from the paired facts page.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

46.2/100

Caution Confidence high

Return On Invested Capital

13%

Metric score 54.6/100

Return On Equity

6%

Metric score 0.0/100

Return On Assets

4.2%

Metric score 26.9/100

Financial Health

Current Ratio
4.61x
Quick Ratio
2.41x
Debt to Equity
0.28x

Strengths

Debt-to-equity and Revenues YoY

Watchpoints

Return On Equity, Return On Assets, and NetIncomeLoss YoY

Calculation methodology and other links

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • Revenues YoY using available TTM or quarter comparison; basis shown per metric
  • Net Income YoY using available TTM or quarter comparison; basis shown per metric
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .